Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.

Pharmacogenomics - 1 Jan 2014

Chen Shuguang, St Jean Pamela, Borland Julie, Song Ivy, Yeo Astrid J, Piscitelli Stephen, Rubio Justin P

Abstract excerpt

AIM: To evaluate potential pharmacogenetic effects of UGT1A1 polymorphisms on the pharmacokinetics (PK) of dolutegravir (Tivicay®; ViiV Healthcare, NC, USA), an HIV-1 integrase inhibitor. PATIENTS & METHODS: Analysis of pooled data from nine Phase I and II clinical studies was undertaken for 89 subjects receiving repeat dolutegravir 50 mg once daily (tablet formulation) who were genotyped for known UGT1A1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucuronosyltransferase
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase

Share to Oxazines

Share to Piperazines

Share to Pyridones

Source

Identifiers

PMID: 24329186
DOI: 10.2217/pgs.13.190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.PMID 24329186Read ↗

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.Semantic proximity Read ↗

Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.Semantic proximity Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.Semantic proximity Read ↗

Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity.Semantic proximity Read ↗

Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency VirusSemantic proximity Read ↗

UGT1A1 regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa.Semantic proximity Read ↗

Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.Semantic proximity Read ↗

Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.